Lucid Diagnostics (NASDAQ:LUCD) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Lucid Diagnostics (NASDAQ:LUCD) from a hold rating to a sell rating in a research note published on Saturday morning.

A number of other research analysts have also weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Lucid Diagnostics in a research note on Monday, December 29th. Ascendiant Capital Markets lifted their price objective on Lucid Diagnostics from $8.00 to $8.25 and gave the company a “buy” rating in a research report on Wednesday, December 10th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Lucid Diagnostics currently has a consensus rating of “Moderate Buy” and an average target price of $3.94.

Lucid Diagnostics Stock Performance

Shares of LUCD opened at $1.40 on Friday. Lucid Diagnostics has a 1 year low of $0.95 and a 1 year high of $1.80. The company’s 50 day simple moving average is $1.29 and its 200 day simple moving average is $1.18. The company has a market capitalization of $192.75 million, a price-to-earnings ratio of -1.35 and a beta of 1.18.

Institutional Investors Weigh In On Lucid Diagnostics

A number of institutional investors have recently bought and sold shares of LUCD. Bank of America Corp DE raised its stake in Lucid Diagnostics by 41.5% during the third quarter. Bank of America Corp DE now owns 40,663 shares of the company’s stock worth $41,000 after purchasing an additional 11,917 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Lucid Diagnostics by 35.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 86,302 shares of the company’s stock valued at $129,000 after purchasing an additional 22,727 shares during the last quarter. Quadrature Capital Ltd purchased a new stake in shares of Lucid Diagnostics during the 2nd quarter valued at $29,000. Centiva Capital LP purchased a new stake in shares of Lucid Diagnostics during the 3rd quarter valued at $25,000. Finally, Sprott Inc. acquired a new stake in shares of Lucid Diagnostics during the 3rd quarter worth $25,000. 74.01% of the stock is currently owned by hedge funds and other institutional investors.

About Lucid Diagnostics

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.